期刊
SPRINGERPLUS
卷 4, 期 -, 页码 -出版社
SPRINGER INTERNATIONAL PUBLISHING AG
DOI: 10.1186/s40064-015-0943-5
关键词
Immunotoxin; in vivo antitumor effectiveness; Colorectal cancer; GPA33; Ribotoxin alpha-sarcin
Tagging of RNases, such as the ribotoxin alpha-sarcin, with the variable domains of antibodies directed to surface antigens that are selectively expressed on tumor cells endows cellular specificity to their cytotoxic action. A recombinant single-chain immunotoxin based on the ribotoxin alpha-sarcin (IMTXA33 alpha S), produced in the generally regarded as safe (GRAS) yeast Pichia pastoris, has been recently described as a promising candidate for the treatment of colorectal cancer cells expressing the glycoprotein A33 (GPA33) antigen, due to its high specific and effective cytotoxic effect on in vitro assays against targeted cells. Here we report the in vivo antitumor effectiveness of this immunotoxin on nude mice bearing GPA33-positive human colon cancer xenografts. Two sets of independent assays were performed, including three experimental groups: control (PBS) and treatment with two different doses of immunotoxin (50 or 100 mu g/injection) (n = 8). Intraperitoneal administration of IMTXA33 alpha S resulted in significant dose-dependent tumor growth inhibition. In addition, the remaining tumors excised from immunotoxin-treated mice showed absence of the GPA33 antigen and a clear inhibition of angiogenesis and proliferative capacity. No signs of immunotoxin-induced pathological changes were observed from specimens tissues. Overall these results show efficient and selective cytotoxic action on tumor xenografts, combined with the lack of severe side effects, suggesting that IMTXA33 alpha S is a potential therapeutic agent against colorectal cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据